American Century Companies Inc. Has $11.19 Million Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

American Century Companies Inc. grew its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 8.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 146,823 shares of the company’s stock after purchasing an additional 10,855 shares during the period. American Century Companies Inc. owned about 0.09% of Dr. Reddy’s Laboratories worth $11,186,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of RDY. GAMMA Investing LLC increased its holdings in shares of Dr. Reddy’s Laboratories by 54.7% during the 1st quarter. GAMMA Investing LLC now owns 721 shares of the company’s stock valued at $53,000 after acquiring an additional 255 shares during the last quarter. Contravisory Investment Management Inc. acquired a new position in shares of Dr. Reddy’s Laboratories during the 1st quarter valued at about $189,000. CWM LLC increased its holdings in shares of Dr. Reddy’s Laboratories by 18.9% during the 1st quarter. CWM LLC now owns 2,584 shares of the company’s stock valued at $190,000 after acquiring an additional 410 shares during the last quarter. Wealthstream Advisors Inc. acquired a new position in shares of Dr. Reddy’s Laboratories during the 2nd quarter valued at about $203,000. Finally, Legacy Capital Group California Inc. acquired a new position in shares of Dr. Reddy’s Laboratories during the 2nd quarter valued at about $204,000. 14.02% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Barclays increased their price objective on Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a report on Tuesday, July 30th.

Dr. Reddy’s Laboratories Price Performance

Shares of NYSE:RDY opened at $78.54 on Monday. The business has a 50 day moving average price of $81.16 and a 200 day moving average price of $75.72. Dr. Reddy’s Laboratories Limited has a twelve month low of $63.72 and a twelve month high of $84.46. The company has a market cap of $13.11 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 1.74 and a beta of 0.55. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Saturday, July 27th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.10). Dr. Reddy’s Laboratories had a net margin of 19.28% and a return on equity of 20.32%. The business had revenue of $919.80 million for the quarter, compared to the consensus estimate of $861.68 million. Research analysts predict that Dr. Reddy’s Laboratories Limited will post 4.11 earnings per share for the current year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.